QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)

Sarepta Therapeutics - SRPT Stock Forecast, Price & News

$120.86
-2.03 (-1.65%)
(As of 01/30/2023 04:21 PM ET)
Add
Compare
Today's Range
$120.72
$123.00
50-Day Range
$110.55
$132.13
52-Week Range
$61.28
$134.08
Volume
601,372 shs
Average Volume
1.05 million shs
Market Capitalization
$10.61 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$150.14

Sarepta Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
23.7% Upside
$150.14 Price Target
Short Interest
Healthy
7.03% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.65
Upright™ Environmental Score
News Sentiment
1.64mentions of Sarepta Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$94,311 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($8.09) to ($3.64) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

212th out of 1,049 stocks

Pharmaceutical Preparations Industry

102nd out of 514 stocks


SRPT stock logo

About Sarepta Therapeutics (NASDAQ:SRPT) Stock

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Receive SRPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SRPT Stock News Headlines

7 Biotech Stocks That Will Make You Rich in 10 Years
SRPT.MW - | Stock Price & Latest News | Reuters
Solar Industry at Start of Long Bull Run?
The U.S. solar industry generated nearly $33 billion of private investment in the American economy in 2021 -- and analysts say it looks like the start of a long solar bull market. Leading the way is the just-signed Inflation Reduction Act of 2022. With its generous investment tax credits, the Act is expected to triple U.S. solar energy production over the next 5 years.
9 Analysts Have This to Say About Sarepta Therapeutics
Needham Keeps Their Buy Rating on Sarepta Therapeutics (SRPT)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
RBC Capital Keeps Their Buy Rating on Sarepta Therapeutics (SRPT)
Robert W. Baird Reaffirms Their Buy Rating on Sarepta Therapeutics (SRPT)
Sarepta’s Gene Therapy Set for Quick FDA Review
Sarepta Therapeutics Unusual Options Activity
See More Headlines
Receive SRPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SRPT Company Calendar

Last Earnings
11/02/2022
Today
1/30/2023
Next Earnings (Estimated)
3/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SRPT
Previous Symbol
NASDAQ:AVII
Employees
840
Year Founded
1980

Price Target and Rating

Average Stock Price Forecast
$150.14
High Stock Price Forecast
$190.00
Low Stock Price Forecast
$114.00
Forecasted Upside/Downside
+24.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$-418,780,000.00
Pretax Margin
-81.11%

Debt

Sales & Book Value

Annual Sales
$701.89 million
Book Value
$10.66 per share

Miscellaneous

Free Float
82,165,000
Market Cap
$10.61 billion
Optionable
Optionable
Beta
1.04

Social Links


Key Executives

  • Douglas S. IngramDouglas S. Ingram
    President, Chief Executive Officer & Director
  • Ian M. Estepan
    Executive VP, Chief Financial & Accounting Officer
  • Louise Rodino-KlapacLouise Rodino-Klapac
    Chief Scientific Officer & Executive VP
  • Bilal Arif
    Chief Technical Operations Officer
  • Dallan Murray
    Chief Customer Officer & Senior Vice President













SRPT Stock - Frequently Asked Questions

Should I buy or sell Sarepta Therapeutics stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SRPT shares.
View SRPT analyst ratings
or view top-rated stocks.

What is Sarepta Therapeutics' stock price forecast for 2023?

9 equities research analysts have issued 12-month price objectives for Sarepta Therapeutics' shares. Their SRPT share price forecasts range from $114.00 to $190.00. On average, they anticipate the company's share price to reach $150.14 in the next twelve months. This suggests a possible upside of 23.2% from the stock's current price.
View analysts price targets for SRPT
or view top-rated stocks among Wall Street analysts.

How have SRPT shares performed in 2023?

Sarepta Therapeutics' stock was trading at $129.58 at the beginning of the year. Since then, SRPT shares have decreased by 6.0% and is now trading at $121.83.
View the best growth stocks for 2023 here
.

When is Sarepta Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our SRPT earnings forecast
.

How were Sarepta Therapeutics' earnings last quarter?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced its quarterly earnings results on Wednesday, November, 2nd. The biotechnology company reported ($2.94) EPS for the quarter, missing the consensus estimate of ($1.21) by $1.73. The biotechnology company had revenue of $230.30 million for the quarter, compared to the consensus estimate of $234.55 million. Sarepta Therapeutics had a negative trailing twelve-month return on equity of 97.37% and a negative net margin of 81.76%. Sarepta Therapeutics's revenue for the quarter was up 21.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.60) EPS.

What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO?

15 employees have rated Sarepta Therapeutics Chief Executive Officer Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among the company's employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Sarepta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and Walt Disney (DIS).

What is Sarepta Therapeutics' stock symbol?

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."

Who are Sarepta Therapeutics' major shareholders?

Sarepta Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.83%), Allspring Global Investments Holdings LLC (0.43%), National Bank of Canada FI (0.34%), Pinnacle Associates Ltd. (0.11%), Comerica Bank (0.09%) and Peregrine Capital Management LLC (0.07%). Insiders that own company stock include David T Howton, Douglas S Ingram, Hans Lennart Rudolf Wigzell, Joseph Bratica, Louise Rodino-Klapac, M Kathleen Behrens, Michael Andrew Chambers, Richard Barry and Stephen Mayo.
View institutional ownership trends
.

How do I buy shares of Sarepta Therapeutics?

Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sarepta Therapeutics' stock price today?

One share of SRPT stock can currently be purchased for approximately $121.83.

How much money does Sarepta Therapeutics make?

Sarepta Therapeutics (NASDAQ:SRPT) has a market capitalization of $10.69 billion and generates $701.89 million in revenue each year. The biotechnology company earns $-418,780,000.00 in net income (profit) each year or ($8.21) on an earnings per share basis.

How many employees does Sarepta Therapeutics have?

The company employs 840 workers across the globe.

Does Sarepta Therapeutics have any subsidiaries?
The following companies are subsidiares of Sarepta Therapeutics: Eisai, Myonexus Therapeutics, ST International Holdings Two Inc., Sarepta Securities Corp., and Sarepta Therapeutics Three LLC.
Read More
How can I contact Sarepta Therapeutics?

Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The official website for the company is www.sareptatherapeutics.com. The biotechnology company can be reached via phone at (617) 274-4000, via email at investors@sarepta.com, or via fax at 425-354-5038.

This page (NASDAQ:SRPT) was last updated on 1/30/2023 by MarketBeat.com Staff